Document is current
Any future updates will be listed below
-
Authors
Clerici, Sara https://orcid.org/0000-0002-3911-9944
Podrini, Christine https://orcid.org/0000-0002-5391-3378
Stefanoni, Davide https://orcid.org/0000-0002-7756-6788
Distefano, Gianfranco
Cassina, Laura https://orcid.org/0000-0002-7350-3069
Steidl, Maria Elena
Tronci, Laura
Canu, Tamara https://orcid.org/0000-0002-4589-9377
Chiaravalli, Marco
Spies, Daniel
Bell, Thomas A 3rd
Costa, Ana SH
Esposito, Antonio
D’Alessandro, Angelo https://orcid.org/0000-0002-2258-6490
Frezza, Christian https://orcid.org/0000-0002-3293-7397
Bachi, Angela https://orcid.org/0000-0003-4842-6556
Boletta, Alessandra https://orcid.org/0000-0002-4704-4006
-
Funding
Funding for this research was provided by:
Italy Ministry of Health | Agenzia Italiana del Farmaco, Ministero della Salute (RF-2018-12368254)
Italy Ministry of Health | Agenzia Italiana del Farmaco, Ministero della Salute (GR-2016-02364851)
Fondazione AIRC per la ricerca sul cancro ETS (IG2019-23513)
- License Information
-
More Information
Article History
Received: 6 October 2023
Revised: 11 April 2024
Accepted: 12 April 2024
First Online: 29 April 2024
Disclosure and competing interests statement
: AB, CP, and MC are co-inventors on patents related to metabolic interventions in Polycystic Kidney Disease including one on 2DG use in PKD and one on the silencing of ASNS for PKD. The remaining authors declare no competing interests.
